APAC Lymphedema Treatment Market - Industry Trends and Forecast to 2031

List of Tables

Asia-Pacific lymphedema treatment market is expected to reach USD 272,372.38 thousand by 2030 from USD 112,385.78 thousand in 2022 growing at the CAGR of 12.0% in the forecast period of 2023 to 2030.

Market Segmentation:

Asia-Pacific Lymphedema Treatment Market, By Treatment Type (Compression Therapy, Surgery, Drug Therapy, Laser Therapy, and Others), Treatment (Primary Lymphedema and Secondary Lymphedema), Affected Area (Genital, Lower Extremity, Upper Extremity, and Others), Age Group (Adult and Geriatric), Route of Administration (Oral, Injectable and Others), End User (Hospitals, Ambulatory Surgical Centres, Speciality Clinics and Others), Distribution Channel (Direct tender, Pharmacy stores, and Others), Country (Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines , Vietnam, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2030.

Overview of Asia-Pacific Veterinary Lymphedema Treatment Market Dynamics:

Driver
Rising number of lymphedema cases around the globe
Restrain
High costs of treatment
Opportunity
Partnership and agreement by market players

Market Players

Some of the key market players for Asia-Pacific veterinary lymphedema treatment market are listed below:

medi GmbH & Co. KG
PAUL HARTMANN AG
3M
Convatec Inc.
JUZO
SIGVARIS GROUP
Sanyleg Srl a socio unico
AIROS Medical, Inc.
Tactile Medical
Cardinal Health
Essity (BSN medical GmbH)
Smith+Nephew
Huntleigh Healthcare Limited
Avet Pharmaceuticals Inc
KOYA MEDICAL

1 INTRODUCTION 20

1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 OVERVIEW OF THE ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET 20
1.4 LIMITATIONS 22
1.5 MARKETS COVERED 22

2 MARKET SEGMENTATION 25

2.1 MARKETS COVERED 25
2.2 GEOGRAPHICAL SCOPE 26
2.3 YEARS CONSIDERED FOR THE STUDY 27
2.4 CURRENCY AND PRICING 27
2.5 DBMR TRIPOD DATA VALIDATION MODEL 28
2.6 MULTIVARIATE MODELLING 31
2.7 PRODUCT TYPE LIFELINE CURVE 31
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 32
2.9 DBMR MARKET POSITION GRID 33
2.10 MARKET END USER COVERAGE GRID 34
2.11 VENDOR SHARE ANALYSIS 35
2.12 SECONDARY SOURCES 36
2.13 ASSUMPTIONS 36

3 EXECUTIVE SUMMARY 37

4 PREMIUM INSIGHTS 41

4.1 PESTEL'S ANALYSIS 42
4.2 PORTER'S MODEL 43

5 PIPELINE ANALYSIS FOR ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET 44

6 EPIDEMIOLOGY 45

7 REGULATORY GUIDELINES FOR ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET 46

7.1 U.S. 46
7.2 EUROPE 47
7.3 INDIA 47
7.4 MEXICO 48
7.5 CANADA 48

8 MARKET OVERVIEW 50

8.1 DRIVERS 52
- 8.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES ASIA-PACIFICLY 52
- 8.1.2 INCREASE IN THE PREVALENCE OF CANCERS 52
- 8.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES 53
- 8.1.4 AVAILABILITY OF MULTIPLE THERAPIES FOR LYMPHEDEMA 53
8.2 RESTRAINTS 54
- 8.2.1 HIGH COST OF TREATMENT 54
- 8.2.2 LACK OF AWARENESS ABOUT THE DISEASE 55
8.3 OPPORTUNITIES 55
- 8.3.1 INCREASING DRUG APPROVALS 55
- 8.3.2 RISING PARTNERSHIPS AND AGREEMENTS BY MAJOR PLAYERS 56
8.4 CHALLENGES 56
- 8.4.1 NO PERMANENT CURE FOR LYMPHEDEMA 56
- 8.4.2 LIMITED REIMBURSEMENT SCENARIO 56

9 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE 58

9.1 OVERVIEW 59
9.2 COMPRESSION THERAPY 60
- 9.2.1 COMPRESSION PUMPS 61
- 9.2.2 COMPRESSION GARMENTS 61
  - 9.2.2.1 COMPRESSION STOCKINGS 61
  - 9.2.2.2 COMPRESSION SLEEVES 61
  - 9.2.2.3 OTHERS 62
- 9.2.3 COMPRESSION BANDAGES & WRAPS 62
- 9.2.4 OTHERS 62
  - 9.2.4.1 STATIC COMPRESSION THERAPY 62
  - 9.2.4.2 DYNAMIC COMPRESSION THERAPY 62
9.3 SURGERY 63
- 9.3.1 LYMPHOVENOUS TRANSPLANT 63
- 9.3.2 LYMPHATICOVENOUS ANASTOMOSIS 63
- 9.3.3 LIPOSUCTION 64
- 9.3.4 OTHERS 64
9.4 DRUG THERAPY 64
- 9.4.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) 65
- 9.4.2 RETINOIDS 65
- 9.4.3 ANTIBIOTICS 65
- 9.4.4 OTHERS 65
9.5 LASER THERAPY 66
9.6 OTHERS 67

10 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TYPE 68

10.1 OVERVIEW 69
10.2 SECONDARY LYMPHEDEMA 70
10.3 PRIMARY LYMPHEDEMA 71
- 10.3.1 LYMPHEDEMA PRAECOX (MEIGE DISEASE) 71
- 10.3.2 CONGENITAL LYMPHEDEMA 72
- 10.3.3 LYMPHEDEMA TARDA 72

11 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA 73

11.1 OVERVIEW 74
11.2 LOWER EXTREMITY 75
11.3 UPPER EXTREMITY 76
11.4 GENITALIA 77

12 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP 78

12.1 OVERVIEW 79
12.2 ADULT 80
12.3 GERIATRIC 81
12.4 PEDIATRIC 81

13 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 82

13.1 OVERVIEW 83
13.2 ORAL 84
13.3 INJECTABLE 85
13.4 TOPICAL 86

14 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY END USER 87

14.1 OVERVIEW 88
14.2 HOSPITAL 89
14.3 SPECIALTY CLINICS 90
14.4 AMBULATORY SURGICAL CENTERS 91
14.5 OTHERS 92

15 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 93

15.1 OVERVIEW 94
15.2 PHARMACY STORES 95
15.3 DIRECT TENDER 96
15.4 OTHERS 97

16 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY REGION 98

16.1 ASIA-PACIFIC 99
- 16.1.1 CHINA 103
- 16.1.2 JAPAN 107
- 16.1.3 INDIA 111
- 16.1.4 SOUTH KOREA 114
- 16.1.5 AUSTRALIA 118
- 16.1.6 INDONESIA 122
- 16.1.7 SINGAPORE 126
- 16.1.8 PHILIPPINES 130
- 16.1.9 THAILAND 134
- 16.1.10 MALAYSIA 138
- 16.1.11 VIETNAM 142
- 16.1.12 REST OF ASIA-PACIFIC 146

17 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, COMPANY LANDSCAPE 147

17.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 147

18 COMPANY PROFILE 148

18.1 TACTILE MEDICAL 148
- 18.1.1 COMPANY SNAPSHOT 148
- 18.1.2 REVENUE ANALYSIS 148
- 18.1.3 COMPANY SHARE ANALYSIS 149
- 18.1.4 PRODUCT PORTFOLIO 149
- 18.1.5 RECENT DEVELOPMENT 149
18.2 ESSITY (BSN MEDICAL GMBH) 150
- 18.2.1 COMPANY SNAPSHOT 150
- 18.2.2 COMPANY SHARE ANALYSIS 150
- 18.2.3 PRODUCT PORTFOLIO 151
- 18.2.4 RECENT DEVELOPMENT 151
18.3 3M 152
- 18.3.1 COMPANY SNAPSHOT 152
- 18.3.2 REVENUE ANALYSIS 152
- 18.3.3 COMPANY SHARE ANALYSIS 153
- 18.3.4 PRODUCT PORTFOLIO 153
- 18.3.5 RECENT DEVELOPMENTS 153
18.4 CARDINAL HEALTH 154
- 18.4.1 COMPANY SNAPSHOT 154
- 18.4.2 REVENUE ANALYSIS 154
- 18.4.3 COMPANY SHARE ANALYSIS 155
- 18.4.4 PRODUCT PORTFOLIO 155
- 18.4.5 RECENT DEVELOPMENT 155
18.5 LOHMANN & RAUSCHER GMBH & CO. KG 156
- 18.5.1 COMPANY SNAPSHOT 156
- 18.5.2 COMPANY SHARE ANALYSIS 156
- 18.5.3 PRODUCT PORTFOLIO 157
- 18.5.4 RECENT DEVELOPMENT 157
18.6 AIROS MEDICAL, INC. 158
- 18.6.1 COMPANY SNAPSHOT 158
- 18.6.2 PRODUCT PORTFOLIO 158
- 18.6.3 RECENT DEVELOPMENT 158
18.7 AVET PHARMACEUTICALS INC. 159
- 18.7.1 COMPANY SNAPSHOT 159
- 18.7.2 PRODUCT PORTFOLIO 159
- 18.7.3 RECENT DEVELOPMENT 159
18.8 BIOCOMPRESSION SYSTEMS 160
- 18.8.1 COMPANY SNAPSHOT 160
- 18.8.2 PRODUCT PORTFOLIO 160
- 18.8.3 RECENT DEVELOPMENT 160
18.9 CONVATEC INC. 162
- 18.9.1 COMPANY SNAPSHOT 162
- 18.9.2 PRODUCT PORTFOLIO 162
- 18.9.3 RECENT DEVELOPMENT 162
18.10 HERANTIS PHARMA PLC 163
- 18.10.1 COMPANY SNAPSHOT 163
- 18.10.2 RECENT DEVELOPMENT 163
18.11 HUNTLEIGH HEALTHCARE LIMITED 164
- 18.11.1 COMPANY SNAPSHOT 164
- 18.11.2 PRODUCT PORTFOLIO 164
- 18.11.3 RECENT DEVELOPMENT 164
18.12 JUZO 165
- 18.12.1 COMPANY SNAPSHOT 165
- 18.12.2 PRODUCT PORTFOLIO 165
- 18.12.3 RECENT DEVELOPMENT 165
18.13 KOYA MEDICAL 166
- 18.13.1 COMPANY SNAPSHOT 166
- 18.13.2 PRODUCT PORTFOLIO 166
- 18.13.3 RECENT DEVELOPMENT 166
18.14 MEDI GMBH & CO. KG 167
- 18.14.1 COMPANY SNAPSHOT 167
- 18.14.2 PRODUCT PORTFOLIO 167
- 18.14.3 RECENT DEVELOPMENT 167
18.15 MEGO AFEK LTD 168
- 18.15.1 COMPANY SNAPSHOT 168
- 18.15.2 PRODUCT PORTFOLIO 168
- 18.15.3 RECENT DEVELOPMENT 168
18.16 PAUL HARTMANN AG 170
- 18.16.1 COMPANY SNAPSHOT 170
- 18.16.2 REVENUE ANALYSIS 170
- 18.16.3 PRODUCT PORTFOLIO 171
- 18.16.4 RECENT DEVELOPMENTS 171
18.17 SANYLEG SRL A SOCIO UNICO 172
- 18.17.1 COMPANY SNAPSHOT 172
- 18.17.2 PRODUCT PORTFOLIO 172
- 18.17.3 RECENT DEVELOPMENT 172
18.18 SIGVARIS GROUP 173
- 18.18.1 COMPANY SNAPSHOT 173
- 18.18.2 PRODUCT PORTFOLIO 173
- 18.18.3 RECENT DEVELOPMENTS 174
18.19 SMITH +NEPHEW 175
- 18.19.1 COMPANY SNAPSHOT 175
- 18.19.2 REVENUE ANALYSIS 175
- 18.19.3 PRODUCT PORTFOLIO 176
- 18.19.4 RECENT DEVELOPMENT 176
18.20 THERMOTEK 177
- 18.20.1 COMPANY SNAPSHOT 177
- 18.20.2 PRODUCT PORTFOLIO 177
- 18.20.3 RECENT DEVELOPMENT 177

19 QUESTIONNAIRE 178

20 RELATED REPORTS 182

LIST OF TABLES

TABLE 1 PIPELINE ANALYSIS FOR LYMPHEDEMA TREATMENT: 44
TABLE 2 AN ANNUAL SURVEY OF HOSPITALS IN THE U.S., PUBLISHED IN 2021 53
TABLE 3 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 60
TABLE 4 ASIA-PACIFIC COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION 2021-2030 (USD THOUSAND) 60
TABLE 5 ASIA-PACIFIC COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 61
TABLE 6 ASIA-PACIFIC COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 61
TABLE 7 ASIA-PACIFIC COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 62
TABLE 8 ASIA-PACIFIC SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 63
TABLE 9 ASIA-PACIFIC SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 63
TABLE 10 ASIA-PACIFIC DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 65
TABLE 11 ASIA-PACIFIC DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 65
TABLE 12 ASIA-PACIFIC LASER THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 66
TABLE 13 ASIA-PACIFIC OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 67
TABLE 14 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 70
TABLE 15 ASIA-PACIFIC SECONDARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 70
TABLE 16 ASIA-PACIFIC PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 71
TABLE 17 ASIA-PACIFIC PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 71
TABLE 18 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 75
TABLE 19 ASIA-PACIFIC LOWER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 75
TABLE 20 ASIA-PACIFIC UPPER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 76
TABLE 21 ASIA-PACIFIC GENITALIA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 77
TABLE 22 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 80
TABLE 23 ASIA-PACIFIC ADULT IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 80
TABLE 24 ASIA-PACIFIC GERIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 81
TABLE 25 ASIA-PACIFIC PEDIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 81
TABLE 26 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 84
TABLE 27 ASIA-PACIFIC ORAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 84
TABLE 28 ASIA-PACIFIC INJECTABLE IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 85
TABLE 29 ASIA-PACIFIC TOPICAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 86
TABLE 30 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 89
TABLE 31 ASIA-PACIFIC HOSPITAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 89
TABLE 32 ASIA-PACIFIC SPECIALITY CLINICS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 90
TABLE 33 ASIA-PACIFIC AMBULATORY SURGICAL CENTERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 91
TABLE 34 ASIA-PACIFIC OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 92
TABLE 35 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 95
TABLE 36 ASIA-PACIFIC PHARMACY STORES IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 95
TABLE 37 ASIA-PACIFIC DIRECT TENDER IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 96
TABLE 38 ASIA-PACIFIC OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 97
TABLE 39 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 99
TABLE 40 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 99
TABLE 41 ASIA-PACIFIC COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 100
TABLE 42 ASIA-PACIFIC COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 100
TABLE 43 ASIA-PACIFIC COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 100
TABLE 44 ASIA-PACIFIC SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 100
TABLE 45 ASIA-PACIFIC DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 101
TABLE 46 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 101
TABLE 47 ASIA-PACIFIC PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 101
TABLE 48 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 101
TABLE 49 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 102
TABLE 50 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 102
TABLE 51 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 102
TABLE 52 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 102
TABLE 53 CHINA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 103
TABLE 54 CHINA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 103
TABLE 55 CHINA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 103
TABLE 56 CHINA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 103
TABLE 57 CHINA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 104
TABLE 58 CHINA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 104
TABLE 59 CHINA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 104
TABLE 60 CHINA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 104
TABLE 61 CHINA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 105
TABLE 62 CHINA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 105
TABLE 63 CHINA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 105
TABLE 64 CHINA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 105
TABLE 65 CHINA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 106
TABLE 66 JAPAN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 107
TABLE 67 JAPAN COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 107
TABLE 68 JAPAN COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 107
TABLE 69 JAPAN COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 107
TABLE 70 JAPAN SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 108
TABLE 71 JAPAN DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 108
TABLE 72 JAPAN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 108
TABLE 73 JAPAN PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 108
TABLE 74 JAPAN LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 109
TABLE 75 JAPAN LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 109
TABLE 76 JAPAN LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 109
TABLE 77 JAPAN LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 109
TABLE 78 JAPAN LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 110
TABLE 79 INDIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 111
TABLE 80 INDIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 111
TABLE 81 INDIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 111
TABLE 82 INDIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 111
TABLE 83 INDIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 112
TABLE 84 INDIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 112
TABLE 85 INDIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 112
TABLE 86 INDIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 112
TABLE 87 INDIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 113
TABLE 88 INDIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 113
TABLE 89 INDIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 113
TABLE 90 INDIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 113
TABLE 91 INDIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 113
TABLE 92 SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 114
TABLE 93 SOUTH KOREA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 114
TABLE 94 SOUTH KOREA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 114
TABLE 95 SOUTH KOREA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 114
TABLE 96 SOUTH KOREA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 97 SOUTH KOREA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 98 SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 99 SOUTH KOREA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 100 SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 116
TABLE 101 SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 116
TABLE 102 SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 116
TABLE 103 SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 116
TABLE 104 SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 117
TABLE 105 AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 118
TABLE 106 AUSTRALIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 118
TABLE 107 AUSTRALIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 118
TABLE 108 AUSTRALIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 118
TABLE 109 AUSTRALIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 110 AUSTRALIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 111 AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 112 AUSTRALIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 113 AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 120
TABLE 114 AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 120
TABLE 115 AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 120
TABLE 116 AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 120
TABLE 117 AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 121
TABLE 118 INDONESIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 122
TABLE 119 INDONESIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 122
TABLE 120 INDONESIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 122
TABLE 121 INDONESIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 122
TABLE 122 INDONESIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 123
TABLE 123 INDONESIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 123
TABLE 124 INDONESIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 123
TABLE 125 INDONESIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 123
TABLE 126 INDONESIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 124
TABLE 127 INDONESIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 124
TABLE 128 INDONESIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 124
TABLE 129 INDONESIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 124
TABLE 130 INDONESIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 125
TABLE 131 SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 126
TABLE 132 SINGAPORE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 126
TABLE 133 SINGAPORE COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 126
TABLE 134 SINGAPORE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 126
TABLE 135 SINGAPORE SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 127
TABLE 136 SINGAPORE DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 127
TABLE 137 SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 127
TABLE 138 SINGAPORE PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 127
TABLE 139 SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 128
TABLE 140 SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 128
TABLE 141 SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 128
TABLE 142 SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 128
TABLE 143 SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 129
TABLE 144 PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 145 PHILIPPINES COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 130
TABLE 146 PHILIPPINES COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 130
TABLE 147 PHILIPPINES COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 130
TABLE 148 PHILIPPINES SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 131
TABLE 149 PHILIPPINES DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 131
TABLE 150 PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 131
TABLE 151 PHILIPPINES PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 131
TABLE 152 PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 132
TABLE 153 PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 132
TABLE 154 PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 132
TABLE 155 PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 132
TABLE 156 PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 133
TABLE 157 THAILAND LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 158 THAILAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 134
TABLE 159 THAILAND COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 134
TABLE 160 THAILAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 134
TABLE 161 THAILAND SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 135
TABLE 162 THAILAND DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 135
TABLE 163 THAILAND LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 135
TABLE 164 THAILAND PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 135
TABLE 165 THAILAND LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 136
TABLE 166 THAILAND LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 136
TABLE 167 THAILAND LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 136
TABLE 168 THAILAND LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 136
TABLE 169 THAILAND LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 137
TABLE 170 MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 138
TABLE 171 MALAYSIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 138
TABLE 172 MALAYSIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 138
TABLE 173 MALAYSIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 138
TABLE 174 MALAYSIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 175 MALAYSIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 176 MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 177 MALAYSIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 178 MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 140
TABLE 179 MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 140
TABLE 180 MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 140
TABLE 181 MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 140
TABLE 182 MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 141
TABLE 183 VIETNAM LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 142
TABLE 184 VIETNAM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 142
TABLE 185 VIETNAM COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 142
TABLE 186 VIETNAM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 142
TABLE 187 VIETNAM SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 143
TABLE 188 VIETNAM DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 143
TABLE 189 VIETNAM LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 143
TABLE 190 VIETNAM PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 143
TABLE 191 VIETNAM LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 144
TABLE 192 VIETNAM LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 144
TABLE 193 VIETNAM LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 144
TABLE 194 VIETNAM LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 144
TABLE 195 VIETNAM LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 145
TABLE 196 REST OF ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 146

LIST OF FIGURES

FIGURE 1 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: SEGMENTATION 25
FIGURE 2 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: DATA TRIANGULATION 28
FIGURE 3 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: DROC ANALYSIS 29
FIGURE 4 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL ANALYSIS 30
FIGURE 5 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 30
FIGURE 6 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 32
FIGURE 7 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: DBMR MARKET POSITION GRID 33
FIGURE 8 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: MARKET END USER COVERAGE GRID 34
FIGURE 9 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: VENDOR SHARE ANALYSIS 35
FIGURE 10 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: SEGMENTATION 40
FIGURE 11 INCREASING PREVALENCE OF LYMPHEDEMA AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 41
FIGURE 12 THE COMPRESSION THERAPY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET IN 2023 AND 2030 41
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET 51
FIGURE 14 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2022 59
FIGURE 15 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2022 69
FIGURE 16 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2022 74
FIGURE 17 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2022 79
FIGURE 18 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 83
FIGURE 19 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY END USER, 2022 88
FIGURE 20 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 94
FIGURE 21 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2022 (%) 147